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Abstract: A comprehensive, more physiologically relevant Intensive Control Insulin-Nutrition-
Glucose (ICING) Model is presented and validated using data from critically ill patients. Glucose
utilisation and its endogenous production in particular, are more distinctly expressed. A more
robust glucose absorption model through ingestion is also added. Finally, this model also includes
explicit pathways of insulin kinetics, clearance and utilisation. Identification of critical constant
population parameters is carried out parametrically, optimising one hour forward prediction
errors, while avoiding model identifiability issues. The identified population values are pG =
0.006 min−1, EGPb = 1.16 mmol/min and nI = 0.003 min−1, all of which are within reported
physiological ranges. Insulin sensitivity, SI , is identified hourly for each individual. All other
model parameters are kept at well-known population values or functions of body weight or
surface area. A sensitivity study confirms the validity of limiting time-varying parameters to
SI only. The model achieves median fitting error <1% in data from 173 patients (N = 42,941
hrs in total) who received insulin while in the Intensive Care Unit (ICU) and stayed for more
than 72 hrs. Most importantly, the median per-patient one-hour ahead prediction error is a very
low 2.80% [IQR 1.18, 6.41%]. It is significant that the 75th percentile prediction error is now
within the lower bound of typical glucometer measurement errors of 7–12%. This result further
confirms that the model is suitable for developing model-based insulin therapies, and capable
of delivering tight blood glucose control, in a real-time model based control framework with a
tight prediction error range.
Keywords: model-based control, tight blood glucose control, TGC, blood glucose, insulin
therapy, insulin sensitivity, critical care, predictive performance
1. INTRODUCTION
Since the landmark study in surgical intensive care unit
(ICU) patients by Van Den Berghe et al. (2001), which
reduced mortality 18-45% using tight glycaemic control
(TGC), the attitude towards tolerating hyperglycaemia in
critically ill patients has changed. However, repeating the
results of Van Den Berghe et al. (2001) has been difficult,
and the role of TGC in ICU and suitable glycaemic
ranges have been under scrutiny in recent years (e.g.
Schultz et al., 2008; Preiser, 2009; Vanhorebeek et al.,
2007; Moghissi et al., 2009). However, conclusions are
varied with both success (Van Den Berghe et al., 2006;
Chase et al., 2008; Krinsley, 2004), failure, (The NICE-
SUGAR Study Investigators, 2009) and, primarily, no
clear outcome (e.g. Griesdale et al., 2009; Wiener et al.,
2008).
Although allowing excessive hyperglycaemia and its as-
sociated effects is becoming unacceptable (Preiser and
Devos, 2007), moderately elevated blood glucose levels are
tolerated or recommended (Moghissi et al., 2009) because
of the fear of hypoglycaemia and higher nursing effort
frequently associated with TGC (Preiser and Devos, 2007;
Vanhorebeek et al., 2007). Interestingly, some, but not all,
TGC studies that reported a mortality reduction also had
reduced and relatively low hypoglycaemic rates (Chase
et al., 2008; Krinsley, 2004), whereas almost all other
reports had increased and often excessive hypoglycaemia
(e.g. The NICE-SUGAR Study Investigators, 2009; Brunk-
horst et al., 2008).
Many studies have developed glucose-insulin models with
varying complexity for a wide range of uses, primarily in
research studies of insulin sensitivity (e.g. Chase et al.,
2007; Mari and Valerio, 1997; Bergman et al., 1981; Parker
and Doyle, 2001; Hovorka et al., 2007). For a model to be
successful in TGC, it needs to reflect observable physiology
and known biological mechanisms. In addition, it should be
uniquely identifiable given the limitated clinically available
data. Finally, the most important aspect for a model in
model-based TGC is its predictive ability, where most
studies provide only fitting error as validation (e.g. Hov-
orka et al., 2007; Parker and Doyle, 2001).
This paper presents a more physiologically relevant and
comprehensive model, ICING (Intensive Control Insulin-
Nutrition-Glucose Model), for TGC particularly in the
ICU. The model addresses several incomplete or implicit
physiological aspects from prior models by Chase et al.
(2007) and Lotz et al. (2008). The new model is validated
using clinical data from ICU patients and assessed for both
its fitting, and more critically, predictive performance.
2. GLUCOSE-INSULIN PHYSIOLOGY MODEL
Two clinically validated glucose-insulin models set the
basis of this study. The model from Chase et al. (2007)
was developed and validated for TGC in the ICU. This
model captures the fundamental dynamics seen in ICU pa-
tients, yet has a relatively simple mathematical structure
enabling rapid identification of patient-specific parameters
(Hann et al., 2005). This model only requires measure-
ments in blood glucose levels (BG), therefore it can be
used clinically for real-time identification and control.
The second model from Lotz et al. (2008) was developed
for insulin resistance diagnosis. The modeled insulin sen-
sitivity has high correlation to the euglycaemic hyperin-
sulinemic clamp (EIC) and high repeatability. However
this model cannot be readily applied to TGC because
it requires non-real-time plasma insulin and C-peptide
assays.
Both models perform very well for their specific applica-
tions. However, neither is generic enough to be readily
applied to different clinical settings. The model in Chase
et al. (2007) lacks diffusive mechanism between interstitial
and plasma insulin compartments, making it unsuitable
for modeling relatively low doses of insulin infusion. The
lack of a generic dextrose absorption model also limits
its application. The model in Lotz et al. (2008) does
not include insulin receptor saturation, limiting its use to
low-dose insulin administration. The Intensive Control of
Insulin-Nutrition-Glucose (ICING) Model is developed by
combining the best aspects of these two models:
G˙=−pGG(t)− SIG(t) Q(t)1 + αGQ(t)
+
P (t) + EGPb − CNS
VG
(1)
Q˙= nI(I(t)−Q(t))− nC Q(t)1 + αGQ(t) (2)
I˙ =−nKI(t)− nLI(t)1 + αII(t) − nI(I(t)−Q(t))
+
uex(t)
VI
+ (1− xL)uen
VI
(3)
P˙1 =−d1P1 +D(t) (4)
P˙2 =−min(d2P2, Pmax) + d1P1 (5)
P (t) =min(d2P2, Pmax) + PN(t) (6)
uen(t) = k1e
− I(t)k2k3 when C-peptide data is
not available (7)
The nomenclature for this model is listed in Table 1.
Table 1. Nomenclature for the ICING Model
G Blood glucose level [mmol/L]
Q Interstitial insulin level [mU/L]
I Plasma insulin level [mU/L]
EGP Endogenous glucose production [mmol/min]
EGPb Basal endogenous glucose production [mmol/min]
CNS Central nervous system glucose uptake [mmol/min]
pG Insulin independent glucose removal (ex-
cluding CNS) and the suppression of
EGP from EGPb with respect to G
[min−1]
SI Insulin mediated glucose removal and the
suppression of EGP from EGPb with
respect to G and Q
[L/mU/min]
αG Saturation parameter for insulin medi-
ated glucose removal
[L/mU]
VG Plasma glucose distribution volume [L]
P (t) Glucose appearance in plasma from dex-
trose intake
[mmol/min]
nI Plasma-interstitium insulin diffusion rate [min
−1]
nC receptor-bound insulin degradation [min
−1]
nK insulin clearance through kidneys [min
−1]
nL insulin clearance through liver [min
−1]
αI Saturation parameter for insulin clear-
ance through liver
[L/mU]
uex(t) Exogenous insulin [mU/min]
uen(t) Endogenous insulin [mU/min]
VI Insulin distribution volume [L]
xL First pass hepatic clearance
P1 Glucose level in stomach [mmol]
P2 Glucose level in gut [mmol]
d1 Glucose absorption rate from stomach [min−1]
d2 Glucose absorption rate from gut [min−1]
D(t) Enteral dextrose intake [mmol/min]
PN(t) Parenteral dextrose intake [mmol/min]
Pmax Maximal glucose flux from gut to plasma [mmol/min]
k1 Basal endogenous insulin production [mU/min]
k2, k3 Generic constants for exponential sup-
pression of uen with elevated I
Equation (1) is revised from the glucose compartment in
Chase et al. (2007). Insulin independent glucose removal
(excluding CNS) and the suppression of EGP from EGPb
with respect to G(t) are compounded and represented by
pG. Insulin mediated glucose removal and the suppres-
sion of EGP from EGPb are similarly compounded and
represented by SI . Consequently, SI effectively represents
the whole-body insulin sensitivity, which includes tissue
insulin sensitivity and the action of Glucose Transporter-4
(GLUT-4). The action of GLUT-4 is associated with the
compounding effect of receptor-binding insulin and blood
glucose, and its signaling cascade is also dependent on
metabolic condition and can be affected by medication
(Bryant et al., 2002). Therefore, SI is time varying and
can reflect evolving patient condition. Its variation through
time can be significant, particularly for highly dynamic,
critically ill patients (Lin et al., 2008).
Equations (2) and (3) define the insulin pharmacokinetics,
and are revised from Lotz et al. (2008). Insulin clear-
ance from plasma is saturable, so is its degradation after
receptor binding in the interstitium (Duckworth et al.,
1998). The receptor-bound insulin Q/(1 + αGQ) is also
the portion effective for glucose removal to cells. Hence this
term also appears in Equation (1) for glucose dynamics.
Equations (4)–(6) present the gastric absorption of glu-
cose. This dextrose absorption model is generic, whereas
the equations in Chase et al. (2007) require relatively infre-
quent adjustments in enteral feeding rate. Equation (7) is a
generic representation of endogenous insulin production if
C-peptide data is not available from the patient for specific
identification of its production.
In summary, the ICING model has added CNS and
EGPb in the glucose compartment, and a generic gastric
absorption model compared to Chase et al. (2007). The
insulin kinetics is similar to Lotz et al. (2008), but with
added insulin receptor saturation. The generic expression
of endogenous insulin production is also a new addition,
and reflects observed physiology (Duckworth et al., 1998).
Overall, this model is more comprehensive in physiology
compared to the models from Chase et al. (2007) and
Lotz et al. (2008). The more generic expressions of the
compartments, as oppose to protocol specific, also makes
the ICING model more suitable for testing or designing
different insulin-nutrition protocols.
3. METHODS
Validation of the ICING Model is performed using data
from 173 patients (42,941 total hours) that were on the
SPRINT TGC protocol for ≥3 days, which cohort also
had a statistically significant hospital mortality reductions
(Chase et al., 2008). These patients also had long enough
stays to exhibit periods of both dynamic evolution and
metabolic stability. The median APACHE II score for this
cohort is 19 [IQR 16, 25] and the median age is 64 [IQR 49,
73] yrs old. The percentage of operative patients is 33%.
The introduction of EGPb and its relationship with pG and
SI in the ICING Model requires EGPb, pG and SI to be
identified, rather than adapted from Chase et al. (2007).
Amongst parameters associated with insulin kinetics, nI
also needs to be identified independently because of its
influence on the shape of Q, linking I and G (note that nC
can be calculated from nI (Lotz et al., 2008)). Parameter
identification and model validation were performed in two
stages to avoid identifiability issues, because G is the only
compartment measured in ICU patients.
The first stage focuses on glucose dynamics and identifies
pG and EGPb as model constants in Equation (1). Because
nI is yet to be identified, insulin kinetics equations and
associated constant parameter values from Chase et al.
(2007) are used during this stage:
Q˙=−kQ(t) + kI(t) (8)
I˙ =− nI(t)
1 + αII(t)
+
uex(t)
VI
(9)
The model at this stage is referred to as the “Intermediate
Model”. The second stage focuses on insulin kinetics and
uses the complete model as defined by Equations (1)–(7).
Identification of nI is performed in this stage. Figure 1
illustrates the parameter identification process and the
model stages.
Insulin sensitivity, SI , the critical dynamic parameter, is
identified hourly using an integral based method (Hann
et al., 2005) while a grid search of pG and EGPb values
Fig. 1. Parameter identification process.
was performed in Stage 1. A similar grid search of nI then
follows in Stage 2a. During grid searches, one constant
value for each parameter is applied across the whole co-
hort. Optimal population constant parameter values for
pG, EGPb and nI are chosen from all the combinations
analysed according to the model’s goodness of fit and,
more importantly, the one hour forward prediction accu-
racy, by assuming the current fitted hourly SI for the next
hour. Grid search of pG and EGPb is performed again with
the complete ICING model to confirm these values in Stage
2b. Finally, a sensitivity study (Stage 2c) is performed on
the other parameters treated as population constants (nK ,
nL, nC , and αG). This step verifies the validity of using
population constants for these parameters.
4. RESULTS
4.1 pG and EGPb Identified in the Intermediate Model –
Stage 1
The per-patient median prediction and fitting errors over
the ranges pG = 0.001→ 0.1 [min−1] and EGPb = 0→
3.5 [mmol/min] generally increase diagonally from low pG-
low EGPb region to high pG-high EGPb region. The area
where low fitting and prediction errors occur also have the
least number of large outlying errors. The “per-patient”
analysis weights each patient equally and eliminates any
bias from having different lengths of patient data. The
per-patient analysis also provides an idea of the cohort
characteristic and inter-patient variability.
Given that low pG and low EGPb produced generally low
per-patient fitting and prediction error well within the
typical measurement error of 7–12%, cohort-wise errors
were evaluated to determine the most suitable pG-EGPb
combination. Figure 2 shows the cumulative distribution
function of the fitting error for 3 selected combinations
of pG and EGPb values. These values provided equally
good per-patient fitting and prediction errors, as well as
cohort-wise prediction errors. The best fitting errors, with
the least number of hourly error over measurement error,
is achieved with [pG, EGPb] = [0.006, 1.16]. Both values
are within the reported physiological ranges (e.g. Tappy
et al., 1999; Chambrier et al., 2000; McDonald et al., 2000;
Pillonetto et al., 2002).
Fig. 2. Cumulative distribution functions of fitting errors
with different combinations of pG and EGPb.
4.2 Insulin Kinetics Parameters identified in the ICING
Model – Stage 2a
The median of the 25th, 50th and 75th percentile fitting and
prediction errors for each patient across nI = 10−4 → 0.02
min−1 in the full ICING Model are shown in Figure 3.
It can be seen that nI = 0.003 min−1 provides the best
predictive performance while fitting error is low through
the entire range. This value corresponds to a half-life
within the reported ranges (Mari and Valerio, 1997; Natali
et al., 2000).
(a) Fitting Error (%) (b) Prediction Error (%)
Fig. 3. Fitting and Prediction Error from nI grid search.
Patient 5004 is shown in Figure 4 as an example of typical
model fit using the fully identified ICING Model (Stage
2a in Figure 1). The model is capable of capturing the
patient’s highly variable dynamics during critical illness,
particularly from the 50th hour to the end of stay, where
the insulin requirement varied significantly from hour to
hour. Note that in Figure 4, only hourly insulin levels in
plasma and interstitial are plotted for readability.
The improvements in model performance from the model
of Chase et al. (2007) through Intermediate Model, and
finally the fully identified ICING Model in Equations (1)–
(7) are shown in Table 2. Results are shown on both per-
patient and by cohort basis to highlight any inter-patient
variability in model performance.
Fig. 4. Simulation results on Patient 5004 using the fully
identified ICING Model. In the top panel, the solid
line (–) illustrates the blood glucose model simulation
while crosses (×) represents the actual BG measure-
ments. The second panel demonstrates the plasma
insulin appearance (–) and plasma glucose appearance
(· · ·). The third panel shows the interstitial insulin
(–) and the receptor-bound interstitial insulin (· · ·).
Model fitted SI is displayed in the bottom panel.
Main results in Table 2 show:
(1) Intermediate Model reduces intra-patient variabil-
ity with lower per-patient upper quartile prediction.
(2) Finalized ICING Model reduces inter-patient vari-
ability with lower upper quartile cohort prediction
errors.
Table 2. Comparison of Median and IQR for
Prediction and Fitting Error Between Models
Prediction Error (%) median [IQR]
Chase Model# Intermediate Model ICING Model
pp∗ 5.90 [4.75,7.51] 5.23 [4.20,6.36] 2.80 [1.18,6.41]
bc+ 5.59 [2.46,10.64] 5.02 [2.11,10.34] 2.81 [1.08,6.47]
Fitting Error (%) median [IQR]
pp∗ 1.11 [0.84,1.63] 0.86 [0.58,1.18] 0.50 [0.21,0.99]
bc+ 1.02 [0.41,1.94] 0.71 [0.23,1.44 ] 0.47 [0.20,0.97]
SI (10
−3 L/mU/min) median [IQR]
pp∗ 0.25 [0.11,0.45] 0.21 [0.13,0.41] 0.31 [0.23,0.40]
bc+ 0.24 [0.14,0.40] 0.21 [0.14,0.32] 0.31 [0.20,0.48]
#model from Chase et al. (2007),
∗pp = per-patient, +bc = by cohort
4.3 Re-Identification of pG and EGPb – Stage 2b
Grid search for the re-identification of pG and EGPb near
the previously identified [pG, EGPb] = [0.006, 1.16] from
Section 4.1 re-affirm these values. This combination of pG
and EGPb values provides very low fitting and prediction
errors in the grid search region, and does not require
adjustments.
Table 3. Sensitivity analysis on prediction error, fitting error and SI
Baseline nK nL nC αG
+50% −50% +50% −50% +50% −50% +50% −50%
Prediction Error (%) 2.81 2.82 2.78 2.88 2.73 2.93 2.75 2.74 3.02
median [IQR] [1.08,6.47] [1.09,6.49] [1.05,6.46] [1.12,6.51] [1.03,6.43] [1.13,6.52] [1.04,6.46] [1.03,6.40] [1.17,6.55]
Fitting Error (%) 0.47 0.51 0.43 0.54 0.39 0.54 0.42 0.41 0.62
median [IQR] [0.20,0.97] [0.22,1.02] [0.18,0.90] [0.24,1.08] [0.17,0.84] [0.24,1.08] [0.18,0.88] [0.17,0.87] [0.28,1.17]
SI (10
−3L/mU/min) 0.31 0.35 0.28 0.37 0.26 0.35 0.29 0.39 0.25
median [IQR] [0.20,0.48] [0.22,0.53] [0.18,0.43] [0.24,0.58] [0.17,0.38] [0.22, 0.54] [0.19,0.42] [0.26,0.57] [0.16,0.40]
*Baseline is the model performance when no change is made to the constant parameters, and is the same as in Table 2 for the ICING Model.
4.4 Parameter Sensitivity – Stage 2c
The parameter sensitivity study results for nK , nL, nC
and αG are shown in Table 3. Changes of ±50% from
their final parameter values for the ICING Model have
no clinically (as opposed to statistically) significant effect
on simulation results in terms of prediction error, fitting
error and identified insulin sensitivity, SI . These results
suggest nK , nL, nC and αG can be fixed at their current
population values without over simplifying the model.
5. DISCUSSION
The ICING Model presented in this study is an integration
and improvement of two clinically validated glucose-insulin
physiological models (Chase et al., 2007; Lotz et al., 2008).
This new model has more explicit physiological relevance
without increasing the number of patient-specific param-
eters to be identified. The insulin kinetics is expressed
with distinctive routes for clearance and transport from
plasma, reflecting biological mechanisms. A generic model
for gastric glucose absorption is also introduced.
Parameters for endogenous glucose removal pG, and basal
endogenous glucose production EGPb trade off each other.
Therefore, it is important that they are identified as a
pair. The definition for EGPb implies this parameter stays
constant for any given patient. The decision to keep pG as
a constant is based on its relatively constant behaviour in
ICU patients (Hann et al., 2005). Grid analysis for the
identification of pG and EGPb as constants population
parameters found the most suitable combination of pa-
rameter values within reported physiological ranges.
Glucose uptake is highly correlated with interstitial in-
sulin (Poulin et al., 1994). However, interstitial insulin
concentrations and dynamics are difficult or impossible
to measure experimentally. This study attempted to find
a realistic description of interstitial insulin by linking
plasma insulin and BG response through known biological
mechanisms and parameter identification. The diffusion
rate between plasma and interstitium nI , is the critical
parameter linking I and G, and its population value is
chosen using an exhaustive grid search in a physiological
range. The chosen parameter value provided low fitting
and prediction error in BG, and particularly reduced inter-
patient variability in prediction error.
An important issue also addressed in this study is model
identifiability. Given the limited data available at the bed-
side, it is crucial to maintain a model that is uniquely iden-
tifiable with bedside (glucose) measurements. Although
the model presented in this study requires many popula-
tion assumptions, and resulted in a much simpler structure
compared to many others (e.g. Parker and Doyle, 2001;
Hovorka et al., 2007), it is able to accurately capture
the highly dynamic response in critical illness. Given all
the parameters kept as population constants have been
carefully studied and their sensitivity analysed, this paper
presents a clinically applicable yet comprehensive glucose-
insulin model that is uniquely identifiable for each patient
at any given time.
However, all models have limitations and this model would
benefit from further investigation into some parameters.
The critical parameters are those that influence the shape
of Q/(1 + αGQ), as this level is the ultimate unknown
(being unmeasurable) and the critical link between insulin
and BG response. These parameters are effectively nI and
αG, as the parameters that only appear in the plasma
insulin equation (Equation (3)) can be more readily iden-
tified given insulin and C-peptide measurements.
6. CONCLUSIONS
A new, more comprehensive glucose-insulin model is pre-
sented and validated using data from ICU patients. The
model is capable of accurately capturing long term dy-
namics of a ICU patient’s glucose-insulin response. Insulin
sensitivity SI is the only parameter that is identified
hourly for each individual. Its identification is guaranteed
to be unique given the integral fitting method used in this
study. Population constant parameters pG, EGPb and nI
have been identified in steps to avoid model identifiability
issues. Parameter sensitivity analysis further confirms the
validity of limiting time-varying parameters to SI only.
The model achieved low fitting and, most importantly, low
prediction error when validated on ICU patients. Fitting
errors and the 75th percentile prediction errors were all
well below measurement error for 42,941 hours of data
from 173 patients. The new model outperforms its pre-
decessors, and has greater physiological relevance. This
model therefore offers a platform to develop robust insulin
therapies for tight glycaemic control.
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